Abou-Alfa GK et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1(8). Abstract
Bibeau K et al. Progression-free survival in patients with cholangiocarcinoma with or without FGF/FGFR alterations: A FIGHT-202 post hoc analysis of prior systemic therapy response. JCO Precis Oncol 2022;6:e2100414. Abstract
Carrizosa DR et al. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions. ASCO 2022;Abstract 3006.
Cheng A-L et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862-73. Abstract
Chow et al. IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. AACR 2023;Abstract CT003.
El-Khoueiry AB et al. IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer. Gastrointestinal Cancers Symposium 2023;Abstract 491.
El-Khoueiry AB et al. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer 2022;22(1):377. Abstract
Finn RS et al. Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). ESMO 2022;Abstract LBA34.
Freemantle N et al. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. Eur J Cancer 2022;168:91-8. Abstract
Fulgenzi CAM et al. Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study. Gastrointestinal Cancers Symposium 2023;Abstract 597.
Goyal L et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388(3):228-39. Abstract
Goyal L et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. ASCO 2022;Abstract 4009.
Kelley RK et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(8):995-1008. Abstract
Kelley RK et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023:[Online ahead of print]. Abstract
Melero I et al. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040. ESMO GI 2022;Abstract SO-12.
Oh D-Y et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1(8). Abstract
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). ASCO 2022;Abstract 4006.
Qin S et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial. J Clin Oncol 2023;41(7):1434-43. Abstract
Qin S et al. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial. ESMO 2022;Abstract LBA35.
Qin S et al. Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. ESMO 2022;Abstract LBA36.
Reig M et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681-93. Abstract
Rimini M et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international propensity score matching analysis. ESMO Open 2022;7(6):100591. Abstract
Vogel A et al. Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202. ESMO GI 2022;Abstract O-2.
Yau T et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: Results from cohort 6 of the CheckMate 040 trial. J Clin Oncol 2023;41(9):1747-57. Abstract
Yoo C et al. Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC). ESMO 2022;Abstract 55P.